• 1. Peking University First Hospital & National Clinical Research Center for Skin and Immune Diseases & Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing 100034, P.R.China;
  • 2. School of Public Health, Capital Medical University & Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing 100069, P.R.China;
  • 3. Statistical Information Center of National Health Commission, Beijing 100810, P.R.China;
LUO Yanxia, Email: lyx100@ccmu.edu.cn
Export PDF Favorites Scan Get Citation

Objectives To analyze the epidemiological characteristics of inpatients with skin cancer in China.Methods The medical records of all inpatients with skin cancer in second-level and above hospitals in China from 2015 to 2017 were collected, and the demographic characteristics and regional distribution of inpatients were retrospectively analyzed.Results From 2015 to 2017, the quantity of inpatients with skin cancer in China increased annually. The ratio of male to female was 1.09 to 1, individuals aged 60 to 70 were high incidence age group, and the occupation was primarily farmers. Guangdong province had the largest quantity of inpatients. Among geographic regions, the proportion of inpatients in East China was the largest (34.20%). Among economic regions, the proportion of inpatients in the east was the largest (45.86%).Conclusions The quantity of inpatients with skin cancer in China is on the rise, and there are obvious spatial differences. Therefore, more attention should be paid to the prevention and treatment of skin cancer.

Citation: XU Lili, ZHANG Licheng, TIAN Xue, ZHAO Yuhan, MIAO Zhiwen, XUE Ming, LUO Yanxia. Epidemiological research on inpatients with skin cancer in China. Chinese Journal of Evidence-Based Medicine, 2020, 20(11): 1280-1283. doi: 10.7507/1672-2531.202007025 Copy

  • Previous Article

    Evaluation of the current situation and rationality of electronic prescription in retail pharmacies in Chengdu in the context of “Internet + drug circulation”
  • Next Article

    The efficacy and safety of PCSK9 inhibitor on hypercholesteremia: a meta-analysis